EU OKs AstraZeneca diabetes drug

European regulators have approved AstraZeneca's (AZN) Xigduo treatment for Type 2 diabetes.

The authorization is the first for a drug that combines an SGLT2 inhibitor, which cuts the reabsorption of excess glucose, and metformin, a standard therapy. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs